388 related articles for article (PubMed ID: 27825119)
21. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
Liu Y; Liu A; Li H; Li C; Lin J
Cancer Prev Res (Phila); 2011 Aug; 4(8):1296-305. PubMed ID: 21490132
[TBL] [Abstract][Full Text] [Related]
22. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer.
Qiu JJ; Lin YY; Ye LC; Ding JX; Feng WW; Jin HY; Zhang Y; Li Q; Hua KQ
Gynecol Oncol; 2014 Jul; 134(1):121-8. PubMed ID: 24662839
[TBL] [Abstract][Full Text] [Related]
24. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells.
Syed V; Ulinski G; Mok SC; Ho SM
J Natl Cancer Inst; 2002 Apr; 94(8):617-29. PubMed ID: 11959895
[TBL] [Abstract][Full Text] [Related]
25. Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.
da Silva RF; Yoshida A; Cardozo DM; Jales RM; Paust S; Derchain S; Guimarães F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28513532
[TBL] [Abstract][Full Text] [Related]
26. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
27. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
28. Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.
Zhang L; Zhou D; Guan W; Ren W; Sun W; Shi J; Lin Q; Zhang J; Qiao T; Ye Y; Wu Y; Zhang Y; Zuo X; Connor KL; Xu G
Cell Death Dis; 2017 Dec; 8(12):3214. PubMed ID: 29238081
[TBL] [Abstract][Full Text] [Related]
29. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.
Zhang P; Zhang P; Shi B; Zhou M; Jiang H; Zhang H; Pan X; Gao H; Sun H; Li Z
Cell Death Dis; 2014 Jan; 5(1):e991. PubMed ID: 24407244
[TBL] [Abstract][Full Text] [Related]
30. Long non-coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer.
Cao Y; Shi H; Ren F; Jia Y; Zhang R
Exp Cell Res; 2017 Oct; 359(1):185-194. PubMed ID: 28754469
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
[TBL] [Abstract][Full Text] [Related]
32. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
[TBL] [Abstract][Full Text] [Related]
33. SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.
Chen M; Zeng J; Chen S; Li J; Wu H; Dong X; Lei Y; Zhi X; Yao L
Aging (Albany NY); 2020 Jun; 12(11):10896-10911. PubMed ID: 32516133
[TBL] [Abstract][Full Text] [Related]
34. High GMFG expression correlates with poor prognosis and promotes cell migration and invasion in epithelial ovarian cancer.
Zuo P; Ma Y; Huang Y; Ye F; Wang P; Wang X; Zhou C; Lu W; Kong B; Xie X
Gynecol Oncol; 2014 Mar; 132(3):745-51. PubMed ID: 24486602
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-125b Suppresses Ovarian Cancer Progression via Suppression of the Epithelial-Mesenchymal Transition Pathway by Targeting the SET Protein.
Ying X; Wei K; Lin Z; Cui Y; Ding J; Chen Y; Xu B
Cell Physiol Biochem; 2016; 39(2):501-10. PubMed ID: 27383536
[TBL] [Abstract][Full Text] [Related]
36. High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis.
Hou M; Cheng Z; Shen H; He S; Li Y; Pan Y; Feng C; Chen X; Zhang Y; Lin M; Wang L; Ke Z
Oncotarget; 2015 Nov; 6(34):35813-29. PubMed ID: 26452130
[TBL] [Abstract][Full Text] [Related]
37. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.
Lu H; Liu Y; Wang D; Wang L; Zhou H; Xu G; Xie L; Wu M; Lin Z; Yu Y; Li G
Tumour Biol; 2016 Aug; 37(8):11469-77. PubMed ID: 27012551
[TBL] [Abstract][Full Text] [Related]
38. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer.
Huang RY; Chung VY; Thiery JP
Curr Drug Targets; 2012 Dec; 13(13):1649-53. PubMed ID: 23061545
[TBL] [Abstract][Full Text] [Related]
39. JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells.
Liu RY; Zeng Y; Lei Z; Wang L; Yang H; Liu Z; Zhao J; Zhang HT
Int J Oncol; 2014 May; 44(5):1643-51. PubMed ID: 24573038
[TBL] [Abstract][Full Text] [Related]
40. Crk-like adapter protein regulates CCL19/CCR7-mediated epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinomas.
Cheng S; Guo J; Yang Q; Yang X
Med Oncol; 2015 Mar; 32(3):47. PubMed ID: 25636509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
